Eton Pharmaceuticals, Inc. — FY2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. This is an annual report, not a standalone Q4 filing; selected Q4 results are included below. Unless otherwise stated, financial amounts are in U.S. dollars.
Business context
Eton is an early-stage specialty pharmaceutical company developing, licensing and commercializing products, primarily hospital injectables and pediatric or other liquid formulations. Its first commercial product, Biorphen (ready-to-use phenylephrine injection), received FDA approval in October 2019 and launched in December 2019. The company reported nine disclosed portfolio products: one commercial product, three under FDA review and five late-stage candidates.
Financial performance and liquidity
| Metric | FY2019 | FY2018 |
|---|---|---|
| Revenue | $0.959 million | $0 |
| Product sales / licensing revenue | $0.459 million / $0.500 million | $0 / $0 |
| Gross profit | $0.506 million | $0 |
| R&D expense | $11.555 million | $5.627 million |
| G&A expense | $7.552 million | $4.694 million |
| Net loss | $18.320 million | $12.740 million |
| Net cash used in operating activities | $18.026 million | $8.145 million |
| Cash and cash equivalents at year-end | $12.066 million | $26.735 million |
FY2019 gross margin was approximately 52.8% on total revenue, which included $0.500 million of licensing revenue; product-sales gross profit was approximately $0.006 million on $0.459 million of sales. The company had $15.009 million of current assets and $1.963 million of current liabilities, or reported working capital of $13.0 million. Total assets were $17.072 million.
At December 31, 2019, gross principal under the SWK facility was $5.0 million; long-term debt was reported net of discount at $4.540 million. The facility permits up to $10.0 million of borrowing, subject to specified conditions. It is secured by company assets, carries interest at three-month LIBOR plus 10% (with a 2% LIBOR floor), and requires a minimum cash balance of $3.0 million. The company reported no cash interest paid in 2019.
Changes versus prior period and Q4
- Revenue began in 2019, from the EM-100 licensing transaction and Biorphen launch; FY2018 had no revenue.
- Net loss increased by $5.580 million year over year. R&D more than doubled, reflecting expanded product development; G&A rose primarily due to public-company costs, Biorphen sales and marketing, and added personnel.
- Operating cash use increased by $9.881 million year over year. Year-end cash declined by $14.669 million, after $5.203 million of net financing cash inflows, including the SWK borrowing.
- Q4 2019 revenue was $0.459 million, operating expenses were $2.662 million and net loss was $2.696 million. The filing’s quarterly table reports Q4 loss per share of $0.15.
Outlook, key developments and risks
- Management stated that available funding, Biorphen revenue and potential EM-100 milestones and royalties were expected to fund operations for at least 12 months from the financial statement issuance date. It cautioned that spending, sales and working-capital estimates could differ and additional financing might be needed. No revenue or earnings guidance was provided.
- ET-105’s NDA was under FDA review with a March 17, 2020 target action date. In February 2020, FDA requested revised dosing instructions and a human-factors validation study; Eton expected to complete and submit the study in 2020.
- EM-100 rights were sold to Bausch Health, which is responsible for commercialization. Eton may receive a $1.5 million launch milestone and royalties; the FDA target action date was August 2020 following a prior Complete Response Letter.
- DS-300’s ANDA was accepted for review, with an October 2020 target action date, but the company expected Paragraph IV patent litigation to delay final approval. A February 2020 agreement amendment assigned Eton responsibility for that litigation and increased its share of product profit to 62.5%.
- ET-203’s original NDA received a refuse-to-file letter. Sintetica expected to address FDA concerns and resubmit in 2020. Eton received back its $1.0 million upfront licensing payment in early 2020, repayable if a resubmission is accepted for review.
- Other 2020 development plans included potential NDA submissions for ET-104, ET-103, DS-100 and ET-101. These remain subject to regulatory, study and development requirements.
- Principal risks include continuing losses and cash burn; dependence on FDA review and approval; patent challenges and litigation; reliance on third-party manufacturers and development partners; commercialization and reimbursement uncertainty; and potential dilution or restrictive debt covenants. The CEO has ownership interests in certain counterparties, creating disclosed related-party conflict risks.
Important facts for investors to verify
- Commercial uptake, net sales, pricing, returns and chargebacks for Biorphen following its December 2019 launch.
- FDA status and timing for ET-105, EM-100 and DS-300, including the human-factors study, Bausch’s resubmission and Paragraph IV litigation.
- Actual cash runway against operating cash use, the $3.0 million minimum-cash covenant and any conditions for drawing the remaining SWK facility.
- Timing and cost of planned product submissions, and any changes to management’s stated expectation of funding for at least 12 months.
- Terms and financial implications of related-party arrangements, partner profit shares, royalties, milestones and future equity or debt financing.
- The independent auditor gave an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not provide an internal-control attestation.